Do loss of function variants in LRRK1 and/or LRRK2 increase the risk of developing Parkinson disease?
This case-control cohort study screened 11 095 participants with Parkinson disease and 12 615 controls using next-generation sequencing data for loss of function variants in LRRK1 and LRRK2. No significant enrichment in cases with Parkinson disease (0.205% and 0.117%, respectively) was found compared with controls (0.139% and 0.087%, respectively).
LRRK1 and LRRK2 loss of function variants do not increase the risk of Parkinson disease; kinase inhibition or allele-specific targeting of mutant LRRK2 remain viable therapeutic strategies in a subset of patients with Parkinson disease.
Pathogenic variants in LRRK2 are a relatively common genetic cause of Parkinson disease (PD). Currently, the molecular mechanism underlying disease is unknown, and gain and loss of function (LOF) models of pathogenesis have been postulated. LRRK2 variants are reported to result in enhanced phosphorylation of substrates and increased cell death. However, the double knockout of Lrrk2 and its homologue Lrrk1 results in neurodegeneration in a mouse model, suggesting that disease may occur by LOF. Because LRRK2 inhibitors are currently in development as potential disease-modifying treatments in PD, it is critical to determine whether LOF variants in LRRK2 increase or decrease the risk of PD.
To determine whether LRRK1 and LRRK2 LOF variants contribute to the risk of developing PD.
Design, Setting, and Participants
To determine the prevailing mechanism of LRRK2-mediated disease in human populations, next-generation sequencing data from a large case-control cohort (>23 000 individuals) was analyzed for LOF variants in LRRK1 and LRRK2. Data were generated at 5 different sites and 5 different data sets, including cases with clinically diagnosed PD and neurologically normal control individuals. Data were collected from 2012 through 2017.
Main Outcomes and Measures
Frequencies of LRRK1 and LRRK2 LOF variants present in the general population and compared between cases and controls.
Among 11 095 cases with PD and 12 615 controls, LRRK1 LOF variants were identified in 0.205% of cases and 0.139% of controls (odds ratio, 1.48; SE, 0.571; 95% CI, 0.45-4.44; P = .49) and LRRK2 LOF variants were found in 0.117% of cases and 0.087% of controls (odds ratio, 1.48; SE, 0.431; 95% CI, 0.63-3.50; P = .36). All association tests suggested lack of association between LRRK1 or LRRK2 variants and PD. Further analysis of lymphoblastoid cell lines from several heterozygous LOF variant carriers found that, as expected, LRRK2 protein levels are reduced by approximately half compared with wild-type alleles.
Conclusions and Relevance
Together these findings indicate that haploinsufficiency of LRRK1 or LRRK2 is neither a cause of nor protective against PD. Furthermore, these results suggest that kinase inhibition or allele-specific targeting of mutant LRRK2 remain viable therapeutic strategies in PD.
Blauwendraat C, Reed X, Kia DA, et al. Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease. JAMA Neurol. 2018;75(11):1416–1422. doi:10.1001/jamaneurol.2018.1885
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: